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GLUT4Calorie restriction (CR; ~60% of ad libitum, AL, consumption) improves insulin-stimulated glucose uptake in skel-
etal muscle. The precise cellular mechanism for this healthful outcome is unknown, but it is accompanied by en-
hanced insulin-stimulated activation of Akt. Previous research using Akt2-null mice demonstrated that Akt2 is
essential for the full CR-effect on insulin-stimulated glucose uptake by muscle. However, because Akt2-null
mice were completely deﬁcient in Akt2 in every cell throughout life, it would be valuable to assess the efﬁcacy
of transient, muscle-speciﬁc Akt inhibition for attenuation of CR-effects on glucose uptake. Accordingly, we
used a selective Akt inhibitor (MK-2206) to eliminate the CR-induced elevation in insulin-stimulated Akt2 phos-
phorylation and determined the effects on Akt substrates and glucose uptake. We incubated isolated
epitrochlearis muscles from 9-month-old AL and CR (~60–65% of AL intake for 6 months) rats with or without
MK-2206 andmeasured insulin-stimulated (1.2 nM) glucose uptake and phosphorylation of the insulin receptor
(Tyr1162/1163), pan-Akt (Thr308 and Ser473), Akt2 (Thr308 and Ser473), AS160/TBC1D4 (Thr642), and Filamin
C (Ser2213). Incubation of isolated skeletal muscles with a dose of a selective Akt inhibitor that eliminated the
CR-induced increases in Akt2 phosphorylation prevented CR's effects on insulin-stimulated glucose uptake,
pAS160Thr642 and pFilamin CSer2213 without altering pIRTyr1162/1163. These data provide compelling new evidence
linking the CR-induced increase in insulin-stimulated Akt2 phosphorylation to CR's effects on insulin-mediated
phosphorylation of Akt substrates and glucose uptake in skeletal muscle.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Calorie restriction without malnutrition (~60% of ad libitum, AL, con-
sumption) has been demonstrated to produce numerous health beneﬁts
in various species includingmice, rats, non-human primates, and humans
[1–9]. A hallmark of CR is improved insulin sensitivity, and this beneﬁt is
attributable, in large part, to improved insulin-stimulated glucose uptake
in skeletal muscle [3,10–13]. The cellular mechanism for enhanced
insulin-stimulated glucose uptake by skeletal muscle remains to be fully
elucidated, but it has been demonstrated to occur concomitant with
greater insulin-induced activation of Akt [10,11].
Akt2 has been identiﬁed as the Akt isoform that is crucial for
insulin-stimulated glucose uptake [10,14–17]. Previous studies have
demonstrated that CR leads to increased insulin-stimulated activation
of Akt2 in skeletal muscle [10,11,18]. Akt substrate of 160 kDa (AS160;School of Kinesiology, Room
8109‐2214, USA. Tel.: +1 734
rights reserved.also known as TBC1D4) is a Rab GTPase activating protein (Rab-GAP)
and Akt substrate that is a major mediator of insulin's activation of glu-
cose transport [19]. AS160 has also been identiﬁed to be a speciﬁc sub-
strate of Akt2 [20,21], and CR leads to increased insulin-stimulated
phosphorylation of both Akt2 and AS160 concomitant with elevated
insulin-stimulated glucose transport in rat epitrochlearis muscle [11].
Using Akt2-null mice, McCurdy et al. [10] demonstrated that Akt2
is essential for the full CR-effect on insulin-stimulated glucose uptake
by skeletal muscle. However, because Akt2 expression was complete-
ly absent from all cells throughout the life of these mice, it would be
valuable to use a different experimental approach to more precisely
elucidate Akt2's role in CR-mediated beneﬁts on muscle insulin sensi-
tivity. Accordingly, we incubated isolated rat epitrochlearis muscles
with MK-2206, a potent and selective Akt inhibitor [22–25] and mea-
sured insulin signaling and glucose uptake. Our goal was to identify a
dose of MK-2206 that eliminated the CR-induced elevation in
insulin-stimulated Akt2 phosphorylation (i.e., to reduce the Akt2
phosphorylation of insulin-treated muscles from CR rats to levels
similar to those found in insulin-treated muscles from AL rats) and
determine the functional effects on the AS160 and glucose uptake.
We hypothesized that acutely inhibiting the CR-induced increase in
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CR on insulin-stimulated AS160 phosphorylation and glucose uptake.2. Materials and methods
2.1. Materials
Unless otherwise noted, all chemicals were purchased from Fisher
Scientiﬁc (Hanover Park, IL) or Sigma Chemical (St. Louis, MO).
Reagents and apparatus for SDS-PAGE and immunoblotting were from
Bio-Rad Laboratories (Hercules, CA). Anti-phospho AS160 Thr642
(pAS160Thr642; #3028-P1) was from B-Bridge International (Cupertino,
CA). Anti-phospho Akt Thr308 (pAktThr308; #9275), anti-phospho Akt
Ser473 (pAktSer473; #9272), and anti-rabbit IgG horseradish peroxidase
conjugate (#7074)were fromCell Signaling Technology (Danvers,MA).
Anti-phospho IR Tyr1162/1163 (pIRTyr1162/1163; #44-504G) and anti-IR
(#AHR0271) were from Invitrogen (Camarillo, CA). Anti-AS160 (#07-
741), anti-GLUT4 (#CBL243) and anti-sheep IgG horseradish peroxi-
dase conjugate (#12-342) were from Millipore (Billerica, MA).
Anti-Akt2 (#AF23151) was from R&D Biosystems (Minneapolis, MN).
Anti-Filamin C (#sc-48496), anti-goat IgG horseradish peroxidase con-
jugate (#sc-2020), and anti-mouse IgG horseradish peroxidase conju-
gate (#sc-2060) were from Santa Cruz Biotechnology (Santa Cruz, CA).
Anti-phospho Filamin-C (pFilCSer2213; PB-131) was from Kinasource
(Dundee, Scotland, UK). Akt inhibitor MK-2206 (#S1078) was from
Selleck Chemicals (Houston, TX). 2-Deoxy-D-[3H]glucose ([3H]2-DG)
and [14C]mannitol were from Perkin Elmer (Boston, MA).2.2. Animal care
Procedures for animal care were approved by the University of
Michigan Committee on Use and Care of Animals. Male Fischer
344×Brown Norway rats, both CR rats and their AL controls were
obtained at 8 months of age from the National Institute of Aging (NIA)
Calorie Restricted Rodent Colony. Calorie restriction was initiated at
14 weeks of age in the CR group by the NIA. Rats were housed at the
University of Michigan for approximately 1 month prior to experimen-
tation. During this time the rats were housed individually in shoebox
cages and maintained on a 12–12 h light–dark cycle (lights out at
17:00 h) in speciﬁc pathogen-free conditions. Rats were provided
chow (AL: NIH31 chow; CR: NIH31/NIA fortiﬁed chow) andmaintained
on their respective feeding protocol (AL: free access to chow; CR: ~60–
65% of AL consumption). Ratswere sacriﬁced after ~1 month at theUni-
versity of Michigan facility, when they were ~9 months of age.2.3. Muscle dissection and incubation
Muscle dissectionwas performed as previously described [11]. Mus-
cle strips were subsequently placed in vials containing the appropriate
media, shaken at 45 rpm, continuously gassed (95% O2/5% CO2), and
heated (35 °C) in a water bath. Muscles were incubated in vials
containing 2 ml KHB supplemented with 0.1% bovine serum albumin
(BSA), 2 mM sodium pyruvate, 6 mM mannitol, and either DMSO or
MK-2206 (0.25 μM or 0.5 μM) for 30 min. Muscles were then trans-
ferred to a second vial containing the identical solution as the previous
step, with or without a physiological concentration (1.2 nM) of insulin
for 30 min. Muscles were then transferred to a third vial containing
2 ml KHB/BSA, the same concentration of MK-2206 and insulin as the
previous step, 1 mM 2-DG; (including a ﬁnal speciﬁc activity of
2.25 mCi/mmol [3H]-2-DG), and 9 mMmannitol (including a ﬁnal spe-
ciﬁc activity of 0.022 mCi/mmol [14C]-mannitol) for 20 min. After this
step, muscles were blotted on ﬁlter paper moistened with ice-cold
KHB, trimmed, freeze-clamped using aluminum tongs cooled in liquid
nitrogen, and stored at−80 °C for later processing and analysis.2.4. Muscle lysate preparation
Frozen muscles were weighed, homogenized in ice-cold lysis buffer
(1 ml/muscle strip) using a TissueLyser II homogenizer (Qiagen, Valencia,
CA). The lysis buffer contained T-PER tissue protein extraction reagent
(#PI-78510; Thermo Scientiﬁc, Rockford, IL), 1 mM EDTA, 1 mM EGTA,
2.5 mM sodium pyrophosphate, 1 mM sodium vanadate, 1 mM ß-
glycerophosphate, 1 μg/ml leupeptin, and 1 mM phenylmethylsulfonyl
ﬂuoride. Homogenates were transferred to microfuge tubes, rotated for
1 h at 4 °C, and then centrifuged at 15,000 g for 15 min at 4 °C to remove
insoluble material. Protein concentration was measured using the BCA
protein assay kit (#23227; Thermo Scientiﬁc).
2.5. Immunoprecipitation
Evaluation of Akt2 phosphorylation at either the Thr308 or Ser473
residue has been previously described [11].
2.6. Immunoblotting
Western blotting procedures have been previously described [11].
An equal amount of protein of each sample was mixed with 6×
Laemmli buffer, boiled for 5 min and separated using SDS-PAGE (7%
resolving gel), before being transferred to polyvinylidene ﬂuoride
membranes (PVDF; Millipore). Membranes were blocked in 5% BSA
in TBST (Tris-buffered saline, pH 7.5 plus 0.1% Tween-20) for 1 h at
room temperature and transferred to 5% BSA–TBST with the appro-
priate primary antibody overnight at 4 °C. Membranes were washed
3 times for 5 min in TBST and incubated with secondary antibody
for 1 h at room temperature. Blots were washed 3 times for 5 min
in TBST then washed 2 times for 5 min in TBS and then subjected to
enhanced chemiluminescence (Luminata Forte Western HRP Sub-
strate; #WBLUF0100; Millipore) to visualize protein bands. Immuno-
reactive proteins were quantiﬁed by densitometry (AlphaEase FC;
Alpha Innotech, San Leandro, CA). Values are expressed relative to
the normalized average of the insulin-stimulated samples without in-
hibitor on each blot.
2.7. 2-Deoxy-D-glucose uptake
The calculation of [3H]-2-Deoxy-D-glucose (2-DG) uptake from
skeletal muscle lysates has been previously described [26,27].
2.8. Statistical analysis
Student's t-test was used for comparisons between two groups.
One-way analysis of variance (ANOVA)was used to determine statistical
signiﬁcance for comparison ofmore than two groups. (SigmaPlot version
11.0; Systat Software, San Jose, CA). Data presented as mean±SEM. A P
value≤0.05 was accepted as statistically signiﬁcant.
3. Results
3.1. Total protein abundance
There was no signiﬁcant difference in total protein abundance be-
tween any of the treatment groups for Akt2, AS160, Filamin C, IR, or
GLUT4 (data not shown).
3.2. Akt phosphorylation
There was no signiﬁcant difference between AL and CR groups for
muscles incubated in the absence of insulin and without MK-2206 for
either pan-Akt phosphorylation (Fig. 1, left panel) or Akt2 phosphor-
ylation (Fig. 1, right panel) at the Thr308 site. For insulin-stimulated
muscles incubated without MK-2206, the phosphorylation of both
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signiﬁcantly (P≤0.05) greater for CR versus AL rats. Incubation of
insulin-stimulated CR muscles with MK-2206 (0.5 μM) signiﬁcantly
(P≤0.05) reduced phosphorylation of both pan-AktThr308 and
Akt2Thr308 compared to insulin-stimulated CR muscles incubated
without MK-2206 (Fig. 1). Neither pan-AktThr308 nor Akt2Thr308 phos-
phorylation was signiﬁcantly different in insulin-stimulated AL mus-
cles versus insulin-stimulated CR muscles incubated with MK-2206.
Therewas signiﬁcantly (P≤0.05) greater pan-AktSer473 phosphoryla-
tion for CR versus AL muscles in the absence of insulin and without
MK-2206 (Fig. 2, left panel). Therewas no signiﬁcant difference between
AL and CR groups in the absence of insulin and without MK-2206 for
Akt2Ser473 phosphorylation (Fig. 2, right panel). For insulin-stimulated
muscles incubated without MK-2206, the phosphorylation of both
AktSer473 (Fig. 2, left panel) and Akt2Ser473 (Fig. 2, right panel) was signif-
icantly (P≤0.05) greater for CR versus AL rats. Incubation of
insulin-stimulated CR muscles with MK-2206 (0.5 μM) signiﬁcantly
(P≤0.05) reduced phosphorylation of both pan-AktSer473 and Akt2Ser473
compared to insulin-stimulated CRmuscles incubatedwithoutMK-2206
(Fig. 2). Both pan-AktSer473 and Akt2Ser473 phosphorylation were signiﬁ-
cantly (P≤0.05) reduced in insulin-stimulated AL muscles versus
insulin-stimulated CR muscles incubated with MK-2206.
3.3. AS160/TBC1D4 phosphorylation
There was no signiﬁcant difference between AL and CR groups for
muscles incubated in the absence of insulin and without MK-2206 for
AS160Thr642 phosphorylation (Fig. 3). For insulin-stimulated muscles in-
cubated without MK-2206, AS160Thr642 phosphorylation was signiﬁcant-
ly (P≤0.05) greater for CR versus AL rats. Incubation of insulin-stimulated
CR muscles with MK-2206 (0.5 μM) signiﬁcantly (P≤0.05) reduced
AS160Thr642 phosphorylation compared to insulin-stimulated CRmuscles
incubatedwithoutMK-2206. AS160Thr642 phosphorylationwasnot signif-
icantly different in insulin-stimulated AL muscles versus insulin-
stimulated CR muscles incubated with MK-2206.
3.4. Filamin C phosphorylation
There was no signiﬁcant difference between AL and CR groups for
muscles incubated in the absence of insulin and without MK-2206
for Filamin CSer2213 phosphorylation (Fig. 4). For insulin-stimulatedpAktThr308
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Fig. 1. Left: pan-Akt Thr308 phosphorylation (pAktThr308). Right: Akt2 Thr308 phosphorylat
immunoblotting with phospho-AktThr308 antibody. “ns” indicates no statistical difference
matching letters are not statistically different, and groups with differing letters are statistica
group. The representative blots for Figs. 1–4 and 6 include a vertical line between the ﬁnal
were located between the lanes labeled as CR and CR+MK-2206) are not included in the rep
including the 3 absent lanes is provided in supplementary Figs. S1–S5.muscles incubated without MK-2206, Filamin CSer2213 phosphoryla-
tion was signiﬁcantly (P≤0.05) greater for CR versus AL rats. Incuba-
tion of insulin-stimulated CR muscles with MK-2206 (0.5 μM)
signiﬁcantly (P≤0.05) reduced Filamin CSer2213 phosphorylation
compared to insulin-stimulated CR muscles incubated without
MK-2206. Filamin CSer2213 phosphorylation was not signiﬁcantly dif-
ferent in insulin-stimulated AL muscles versus insulin-stimulated CR
muscles incubated with MK-2206.
3.5. 2-Deoxy-D-glucose uptake
There was no signiﬁcant difference between AL and CR groups for
muscles incubated in the absence of insulin and without MK-2206 for
2-DG uptake (Fig. 5). For insulin-stimulatedmuscles incubatedwithout
MK-2206, 2-DGuptakewas signiﬁcantly (P≤0.05) greater for CRversus
AL rats. Incubation of insulin-stimulated CR muscles with MK-2206
(0.5 μM) signiﬁcantly (P≤0.05) reduced 2-DG uptake compared to
insulin-stimulated CR muscles incubated without MK-2206. 2-DG up-
take was not signiﬁcantly different in insulin-stimulated AL muscles
versus insulin-stimulated CR muscles incubated with MK-2206.
3.6. Insulin receptor phosphorylation
There was no signiﬁcant difference between AL and CR groups for
muscles incubated in the absence of insulin and without MK-2206 for
IRTyr1162/1163 phosphorylation (Fig. 6). For insulin-stimulated muscles
incubated without MK-2206, IRTyr1162/1163 phosphorylation was signif-
icantly (P≤0.05) greater for CR versus AL rats. Insulin-stimulated CR
muscles incubated withMK-2206 (0.5 μM)were not statistically differ-
ent from insulin-stimulated CR muscles incubated without MK-2206,
but were signiﬁcantly (P≤0.05) greater than insulin-stimulated AL
muscles incubated without MK-2206.
3.7. Muscles incubated with 0.25 μM MK-2206
Muscles were evaluated using two MK-2206 doses (0.25 and
0.5 μM) to identify a dose that eliminated CR-effects on Akt2 phosphor-
ylation, and the results revealed that 0.5 μMMK-2206 was effective for
this purpose. Accordingly, the data with 0.5 μMMK-2206were used for
the statistical analyses, and only these data were shown in the repre-
sentative blots of Figs. 1–4 and 6 (i.e., several lanes were removedpAkt2Thr308
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ion (pAkt2Thr308), muscle lysates were immunoprecipitated with Akt2 antibody prior to
between AL and CR groups in the absence of insulin. Insulin-stimulated groups with
lly (P≤0.05) different from each other. Values are means±SE, n=6–10 per treatment
2 lanes (labeled as CR and CR+MK-2206). The vertical line indicates that 3 lanes (that
resentative blots of Figs. 1–4 and 6. For each of the representative blots, another image
Re
la
tiv
e 
Un
its
R
el
at
iv
e 
Un
its
b
b
c
a
c
a
------ ns ------
------ * ------
pAktSer473 pAkt2Ser473
CR+
MK-2206
AL CR AL   CR AL  CR AL  CR CR+
MK-2206
-------BASAL-------- -------------INSULIN------------- -------BASAL-------- -------------INSULIN-------------
-------BASAL-------- -------------INSULIN------------- -------BASAL-------- -------------INSULIN-------------
Fig. 2. Left: pan-Akt Ser473 phosphorylation (pAktSer473). Right: Akt2 Ser473 phosphorylation (pAkt2Ser473), muscle lysates were immunoprecipitated with Akt2 antibody prior to
immunoblotting with phospho-AktSer473 antibody. See Fig. 1 legend for representative blot explanation. *Indicates a statistical (P≤0.05) difference between AL and CR groups in the
absence of insulin. “ns” indicates no statistical difference between AL and CR groups in the absence of insulin. Insulin-stimulated groups with matching letters are not statistically
different, and groups with differing letters are statistically (P≤0.05) different from each other. Values are means±SE, n=6–11 per treatment group.
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eliminated from the blots (Figs. S1–S5) are also available to demon-
strate that no other modiﬁcation was made to the images used in the
representative blots. Examination of the supplementary ﬁgures reveals
that the lower dose ofMK-2206 (0.25 μM) did not appear to completely
eliminate CR-induced increments for phosphorylation of Akt2Thr308
(Fig. S1), AS160Thr642 (Fig. S2) and Filamin CSer2213 (Fig. S3) or to
completely eliminate the CR-induced increase in insulin-stimulated
2-DG uptake (Fig. S6). The CR-induced increase in Akt2Ser473 phosphor-
ylation appeared to be eliminated with either MK-2206 dose (Fig. S4),
and as expected, neither MK-2206 dose appeared to alter IRTyr1162/1163
phosphorylation (Fig. S5).
4. Discussion
CR's effects on insulin sensitivity have been linked to Akt2 because
CR increases insulin-stimulated phosphorylation of muscle Akt2pAS160Thr642
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Fig. 3. AS160/TBC1D4 Thr642 phosphorylation (pAS160Thr642). See Fig. 1 legend for repre-
sentative blot explanation. “ns” indicates no statistical difference between AL and CR
groups in the absence of insulin. Insulin-stimulated groups with matching letters are not
statistically different, and groups with differing letters are statistically (P≤0.05) different
from each other. Values are means±SE, n=6–10 per treatment group.[10,11,18], and mice null for Akt2 have little or no CR-effects on mus-
cle glucose uptake [10]. In this context, we previously hypothesized
that the CR-induced elevation in insulin-stimulated pAkt2 is crucial
for the CR-related improvement in muscle glucose uptake [10].
Akt2-null mice are completely lacking in this protein in all cells
throughout life, and physiologic insulin doses have little or no ability
to stimulate glucose uptake in muscles from Akt2-null mice. Accord-
ingly, the results of transient inhibition of muscle Akt in the current
study provide unique and valuable insights with regard to the mech-
anisms for CR effects on insulin-stimulated glucose uptake. The most
signiﬁcant new information from the current study was that incuba-
tion of isolated skeletal muscles with the dose (0.5 μM) of a potent
and selective allosteric Akt inhibitor MK-2206 [22–25,28–32], that
eliminated the CR-induced increase in pAkt2Thr308 led to concomitant
prevention of CR's effects on both glucose uptake and Thr642 phos-
phorylation of AS160/TBC1D4 without altering pIRTyr1162/1163. The
strikingly similar patterns for pAkt2Thr308, pAS160Thr642, and glucosepFilamin C Ser2213
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Fig. 4. Filamin C Ser2213 phosphorylation (pFilamin CSer2213). See Fig. 1 legend for repre-
sentative blot explanation. “ns” indicates no statistical difference between AL and CR
groups in the absence of insulin. Insulin-stimulated groups with matching letters are not
statistically different, and groups with differing letters are statistically (P≤0.05) different
from each other. Values are means±SE, n=6–11 per treatment group.
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Fig. 5. 2-Deoxy-D-glucose (2-DG) uptake. “ns” indicates no statistical difference between
AL and CR groups in the absence of insulin. Insulin-stimulated groupswithmatching letters
are not statistically different, and groupswith differing letters are statistically (P≤0.05) dif-
ferent from each other. Values are means±SE, n=9–15 per treatment group.
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for greater pAS160Thr642, which in turn, is crucial for increased glu-
cose uptake.
We speciﬁcally assessed Akt2 phosphorylation because this isoform
is crucial for insulin-mediated glucose uptake [14–17], butwe also eval-
uated pan-Akt phosphorylation. Consistent with previous research,
insulin-stimulated muscles from CR versus AL animals had greater
pan-pAktThr308 and pan-pAktSer473 [11]. MK-2206 was similarly effec-
tive for reducing pAkt2Thr308 versus pan-pAktThr308 and for pAkt2Ser473
versus pan-pAktSer473. However, the relative magnitude of the inhibi-
tion by MK-2206 was somewhat greater for phosphorylation of
Ser473 (80% for pAkt2 and 90% for pan-pAkt) compared to Thr308
(54% for pAkt2 and 60% for pan-pAkt). Akt is phosphorylated on
Thr308 by 3-phosphoinositide-dependent protein kinase-1 (PDK1)
and on Ser473 by mammalian target of rapamycin-2 (mTORC2) [33],
but it is uncertain if the current results are related to the distinct kinases
that are responsible for the two phosphorylation sites. Using MK-2206pIRTyr1162/1163
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Fig. 6. Insulin receptor Tyr1162/1163 phosphorylation (pIRTyr1162/1163). See Fig. 1 legend
for representative blot explanation. “ns” indicates no statistical difference between AL
and CR groups in the absence of insulin. Insulin-stimulated groups with matching letters
are not statistically different, and groups with differing letters are statistically (P≤0.05)
different from each other. Values are means±SE, n=6–11 per treatment group.with insulin-stimulated (100 nM) 3T3-L1 cells, Tan et al. [22] previously
reported that the relative extent of inhibition was similar for pan-
pAktSer473 versus pan-pAktThr308. It is unclear if the apparently different
results of these two experiments are related to differences in the models
studied (rat skeletal muscle versus 3T3-L1 cells), differences in insulin
concentrations used (1.2 nM versus 100 nM) or something else. Regard-
less, it is notable that the inhibition of pAkt in both skeletal muscle and
3T3-L1 cells was accompanied by inhibition of insulin-stimulated glucose
uptake.
Filamin C is an actin-binding protein that is highly expressed in
skeletal muscle and believed to be involved with stabilizing and
maintaining the structure of actin ﬁlament networks with cell mem-
branes and/or act as a scaffolding protein [34,35]. Insulin-regulated
remodeling of actin ﬁlaments has been implicated in the control of
both the spatial localization of insulin signaling proteins and translo-
cation of GLUT4 glucose transporter vesicles [36]. Filamin C was pre-
viously identiﬁed as an Akt substrate that in C2C12 myocytes
incubated with insulin becomes phosphorylated on Ser2213 [34]. Al-
though the functional signiﬁcance of the observed insulin-mediated
and Akt-dependent phosphorylation of Filamin C on Ser2213 in skel-
etal muscle is uncertain, the current results for AS160 and Filamin C
demonstrate that the CR-related increase in activation of Akt can be
accompanied by greater phosphorylation of multiple Akt substrates.
Phosphorylation of the insulin receptor on Tyr1162/1163 is impor-
tant for insulin-mediated glucose uptake. Replacement of insulin recep-
tor tyrosine residues 1162 and 1163 compromises insulin-stimulated
kinase activity and glucose uptake [37]. In the current study, insulin-
stimulatedmuscles from CR versus AL rats were characterized by great-
er IRTyr1162/1163 phosphorylation.Most [11,38–40], but not all [41] of the
published studies that have evaluated CR effects on muscle IR function
at submaximally effective insulin levels have not reported diet-related
differences. The observation that MK-2206 eliminated the CR-induced
increase in insulin-stimulated glucose uptake without attenuating
IRTyr1162/1163 phosphorylation in the current study provides evidence
that the CR effect on the IR was not sufﬁcient for increasing glucose
uptake.5. Conclusions
This study provides compelling new evidence that the CR-induced
increase in Akt2 phosphorylation is essential for CR's effect on
insulin-stimulated glucose uptake in skeletal muscle. The current re-
sults implicate the CR-induced increase in Akt2 phosphorylation as a
key mediator of improved insulin sensitivity, a major health beneﬁt of
CR. It will be important for future studies to identify the mechanisms
that account for enhanced insulin-stimulated phosphorylation of Akt2
in response to CR. Although the current results implicate AS160Thr642
as a likely contributor to the CR effect on glucose uptake, the functional
consequences of greater Akt2-mediated phosphorylation of other Akt
substrates (including Filamin C) will require further scrutiny.
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